
CorFlow Therapeutics Secures FDA Approval for MOCA-II Pivotal Study of Innovative Heart Attack Treatment Technology
A pioneer in cardiac treatment for microvascular disease, today announced that the U.S. Food & Drug Administration (FDA) has granted its technology an Investigational Use Exemption (IDE), allowing the pivotal clinical trial to begin in U.S. hospitals. CorFlow will now…












